Patients who have had chemotherapy or radiotherapy within  weeks prior to starting radiation treatment
Participants who have received thoracic radiotherapy to lung fields =<  weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =<  weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =<  weeks prior to starting study treatment is allowed
Participants who have received radiotherapy =<  weeks prior to starting study drug, and who have not recovered to grade  or better from related side effects of such therapy (except alopecia and neuropathy) and/or in whom >= % of the bone marrow was irradiated
Patient who has received radiotherapy =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia), and/or in whom >= % of the bone marrow was irradiated
Radiotherapy within one week prior to starting study treatment.
Prior radiotherapy is acceptable provided the patient has recovered from any radiotherapy related acute toxicities.
Prior radiotherapy is acceptable provided it was applied within  four weeks before starting of this trial and the patient recovered from any radiotherapy related acute toxicities.
Prior radiotherapy or radiosurgery <  weeks prior to starting study treatment
Thoracic radiotherapy to lung fields =<  weeks prior to starting INC or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =<  weeks prior to starting INC or patients who have not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =<  weeks prior to starting INC is allowed
Patients who have received radiotherapy =<  weeks prior to starting study drugs, with exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =<  and/or from whom >= % of the bone marrow was irradiated
Radiotherapy =<  days prior to enrollment; patients must have recovered from all radiotherapy-related toxicities
Patients who have had radiotherapy =<  weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
Patient who has received thoracic radiotherapy to lung fields =<  weeks prior to starting the study treatment or patients who have not recovered from radiotherapyrelated toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =<  weeks prior to starting the study treatment or has not recovered from radiotherapyrelated toxicities; palliative radiotherapy for bone lesions =<  weeks prior to starting study treatment is allowed
Patients who have had radiotherapy ?  weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
CAPMATINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic therapies within the following time frame:\r\n* Any prior treatment with capmatinib, crizotinib, or any other cMET or HGF inhibitor\r\n* Thoracic radiotherapy to lung fields =<  weeks prior to starting capmatinib; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =<  weeks prior to starting capmatinib; palliative radiotherapy for bone lesions =<  weeks prior to starting capmatinib is allowed\r\n* Receipt of any anticancer or investigational agent within  weeks or =<  half-lives of the agent (whichever is longer) prior to the first dose of capmatinib; if previous treatment is a monoclonal antibody, then the treatment must be discontinued at least  weeks before the first dose of capmatinib
CERITINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic therapies within the following time frame:\r\n* Any prior treatment with ceritinib\r\n* Radiotherapy to lung fields =<  weeks prior to starting ceritinib; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =<  weeks prior to starting ceritinib; palliative radiotherapy for bone lesions =<  weeks prior to starting ceritinib is allowed\r\n* Receipt of any cytotoxic chemotherapy, biologic agent, or investigational agent within  weeks prior to the first dose of study drug (within  weeks for nitrosoureas, mitomycin C or liposomal doxorubicin)
Patient who has received thoracic radiotherapy to lung fields =<  weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =<  weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =<  weeks prior to starting study treatment is allowed
Patient who has received thoracic radiotherapy to lung fields =<  weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =<  weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =<  weeks prior to starting study treatment is allowed
Patients who have had radiotherapy =<  weeks prior to starting study drug, or =<  weeks prior to starting study drug in the case of localized radiotherapy (e.g., for analgesic purpose or for lytic lesions at risk of fracture)
Thoracic radiotherapy to lung fields ?  weeks prior to starting INC or patients who have not recovered from radiotherapy-related toxicities
Radiotherapy ?  weeks prior to randomization. Patients must have recovered from all radiotherapy-related toxicities.
Patients who have received radiotherapy =<  weeks prior to starting study drugs, with exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =<  and/or from whom >= % of the bone marrow was irradiated
Patients who have received radiotherapy =<  weeks prior to starting study treatment and/or from whom >= % of the bone marrow was irradiated as determined by the investigator
Patients must be >=  weeks beyond treatment with any chemotherapy or radiotherapy, and must have recovered to =< grade  toxicity for any treatment-limiting toxicity of prior therapy; (exception: patients may have received palliative low dose radiotherapy to the limbs - weeks before this therapy provided pelvis, ribs, sternum, scapulae, vertebrae or skull were not included in the radiotherapy field); also, patients who have received non-chemotherapeutic biologic agents will need to wait at least five half-lives or four weeks, whichever is shorter, from the last day of treatment; exception: no washout of cetuximab or regorafenib is required for patients who have received prior cetuximab or regorafenib and have recovered from any treatment-related toxicities to grade =< 
Patients who have received radiotherapy =<  weeks prior to registration, with the exception of palliative radiotherapy, who have not recovered from side effects of such therapy to baseline or grade =<  and/or from whom >= % of the bone marrow was irradiated are not eligible for participation
Last radiotherapy treatment >=  weeks prior to starting treatment with this protocol and there must be sites of measurable disease that did not receive radiation
Patients who have received radiotherapy =<  weeks prior to starting treatment
Radiotherapy within  days before the first dose of study treatment (within  weeks if given as palliation to bone metastases, if recovered from all toxicities)
Radiotherapy prior to initiation of therapy is allowed to a limited area (e.g., palliative treatment for painful bone metastases), if it is not the sole site of disease; subjects must have completed treatment at least one week prior to starting study drugs, and must have recovered from all treatment-related toxicities
Any radiotherapy within  week of starting treatment on protocol
Radiotherapy within  weeks prior to study registration. Subjects must have recovered from all therapy-related toxicities.
Patients who have received definitive radiotherapy ?  weeks prior to starting study drug, who have not recovered from side effects of such therapy and/or from whom ? % of the bone marrow was irradiated.
Patients who have had radiotherapy =<  weeks prior to starting study drug, or =<  weeks prior to starting study drug in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicities
Last radiotherapy treatment  weeks prior to starting treatment with this protocol  with the exception of palliative radiotherapy  and there must be sites of measurable disease that did not receive radiation
Patient who has received thoracic radiotherapy to lung fields =<  weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy =<  weeks prior to starting the study treatment or has not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =<  weeks prior to starting study treatment is allowed
Radiotherapy (external beam or CyberKnife) =<  days prior to starting study drug, or =<  days prior to study registration in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicities
